Kiniksa Pharmaceuticals Raises 2025 Revenue Guidance for ARCALYST Amid Strong Q1 Performance
Kiniksa Pharmaceuticals International Plc has reported a strong start to 2025, with increased revenue guidance and solid Q1 earnings, positioning the company as a key player in the biotechnology sector.
- Kiniksa Pharmaceuticals International Plc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read